Latest revision as of 18:17, 20 August 2024

Kosar Doraghi, M.D.

Associate Editor-in-Chief, Beth Israel Deaconess Medical Center by Harvard Medical School, Boston, Massachusetts, USA, WikiDoc Scholar

@@ Line 1: / Line 1: @@
 [[User:Kosar Doraghi|Kosar Doraghi, M.D.]][mailto:k.doraghi@yahoo.com]
+=Kosar Doraghi, M.D.=
+==Current Position==
+'''Associate Editor-in-Chief,''' Beth Israel Deaconess Medical Center by Harvard Medical School, Boston, Massachusetts, USA, WikiDoc Scholar
+==Pages Authored/Co-authored/Collaborated==
+<div style="-moz-column-count:8; column-count:3;">
+#[[NEXOBRID]]
+#[[RELYVRIO]]
+#[[Deucravacitinib]]
+#[[Ublituximab-xiiy]]
+#[[LYTGOBI- futibatinib]]
+#[[Tapinarof]]
+#[[Spevigo- spesolimab-sbz]]
+#[[Vericiguat]]
+#[[Dasiglucagon]]
+#[[Ponesimod]]
+#[[Lasmiditan]]
+#[[Nirogacestat]]
+#[[Nedosiran]]
+#[[Ryzneuta]]
+#[[Endocarditis overview]]
+#[[Sparsentan]]
+#[[BRENZAVVY- bexagliflozin]]
+#[[COPD Patient with suspected Exacerbation(New GOLD 2024 Recommendation)]]
+#[[Nirsevimab]]
+#[[Xacduro- sulbactam and durlobactam]]
+#[[EXXUA]]
+#[[Somatrogon-ghla]]
+#[[Aprocitentan]]
+#[[WINREVAIR]]
+#[[Xolremdi]]
+#[[Rytelo]]
+#[[Chronic obstructive pulmonary disease history and symptoms]] New Guidelines 2024
+#[[Chronic renal failure overview]] New Guidelines 2024
+#[[Clinical assessment of lower extremity peripheral arterial disease]] New Guidelines 2024